Barlow Wealth Partners Inc. Takes Position in Eli Lilly and Company (NYSE:LLY)

Barlow Wealth Partners Inc. purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 2,031 shares of the company’s stock, valued at approximately $1,184,000.

Other large investors have also recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the third quarter worth about $27,000. Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $36,000. Family CFO Inc bought a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $40,000. Finally, O Brien Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 70.5% during the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after acquiring an additional 31 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several research reports. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Barclays boosted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. BMO Capital Markets upped their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Finally, Bank of America raised their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Price Performance

LLY stock traded down $2.77 during midday trading on Wednesday, reaching $775.00. The company had a trading volume of 2,010,705 shares, compared to its average volume of 3,076,480. The company has a market capitalization of $736.56 billion, a price-to-earnings ratio of 114.14, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The stock has a 50 day moving average price of $761.22 and a 200-day moving average price of $674.88.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period last year, the firm posted $1.62 earnings per share. The firm’s quarterly revenue was up 26.0% compared to the same quarter last year. Equities research analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be issued a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.